See the CEO’s letter
Our impact on the world remains extraordinary, with 766 million patients reached in 2021
Our strategy and performance
Our strategy is to build a focused medicines company powered by technology leadership in research and development, world-class commercialization, global access and data science.
See more about our strategy here. Or read about our financial performance and performance against our five strategic priorities below.
Improving heart health through digital technology
Cardiovascular disease is a leading cause of death in China. AI Nurse is a digital health app, the result of a collaboration between Novartis and Tencent, that leverages the WeChat social media platform to make it easier for patients with heart failure and other cardiovascular diseases to manage disease progression.Read the story
On the frontline in the fight against malaria
For decades, Novartis has been involved in the fight against malaria, a disease that causes hundreds of thousands of deaths worldwide, most of them in children, despite it being treatable and curable. In Nigeria, Novartis is working with a local partner to drive greater awareness of disease prevention and to train local medicine vendors how to diagnose and treat common childhood illnesses like malaria.Read the story
A Novartis employee finds
her true self
In the mid-1990s, Skye Towers – a Novartis employee based in our Dublin office – realized she didn’t feel comfortable in her own skin. The transition to become Skye took many years, but she succeeded in overcoming the private and public challenges involved in changing gender. Today, she is helping others who want to follow a similar path.Read the story